Ever Supreme Bio Technology Co. Ltd

Ever Supreme Bio Technology Co., Ltd researches, develops, and manufactures drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates through two segments: Cell Preparation Business and Other Operating Business. Its products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for myocardial infarction and stroke; a dendritic cell vaccine in Phase II clinical trials for malignant brain tumor; chimeric antigen receptor immune cells; and allogeneic bone-marrow stem cells for chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company also develops allogeneic umbilical cord mesenchymal stem cells (UMSC01) for cardiovascular diseases and strokes, and engages in the sale of other health products, cell preparations, and investment activities in biotechnology and medical industry businesses. Incorporated in 2016, it is based in Taichung, Taiwan.